



THE UNITED STATES PATENT AND TRADEMARK OFFICE

1646

RECEIVED

AUG 27 2001

TECH CENTER 1600/2900

P#7

In re Application of:

WONG et al.

Serial No.: 09/810,700

Filed: March 16, 2001

Art Unit: 1646

Examiner: Not yet assigned

Atty. Docket No.: 00-149-US

ENDOTHELIAL SPECIFIC  
TARGETING

Pittsburgh, Pennsylvania 15230

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being

**MAILED**

☒ deposited with the United States Postal Service on August 22, 2001 with sufficient postage as first-class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

**FACSIMILE**

☐ transmitted by facsimile on [date] to the U.S. Patent and Trademark Office.

Type Signature Name

Debbie LeDonne

  
(Signature of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

1. ☒ Enclosed is PTO Form 1449 (and a duplicate thereof).
2. ☐ Items listed on the enclosed Form PTO-1449 are not in the English language.
- ☐ For each of the following items, an English-language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
- ☐ For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application:
- ☐ For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609:

3. ☐ Submission in Accordance with 37 CFR § 1.98(d).

Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in Application Serial No. [Ser. No.], filed [Date], of which the present application relies upon for an earlier filing date under 35 U.S.C. 120.

4. ☒ Submission in Accordance with 37 CFR § 1.97(b).

This Information Disclosure Statement is being filed

- ☐ With the application;
- ☐ Within three months of the filing date of a national application;
- ☐ Within three months of the date of entry of the national stage in an international application; or
- ☒ Before the mailing date of a first Office Action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

5. ☐ Submission in Accordance with 37 CFR 1.97(c).

This Information Disclosure Statement is being filed before the first mailing date of either

- ☐ A final action under § 1.113; or
- ☐ A notice of allowance under § 1.311.
- ☐ A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or
- ☐ This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.
6. ☐ **Submission in Accordance with 37 CFR 1.97(d).**
- This Information Disclosure Statement is being filed after the mailing date of either
- ☐ A final action under § 1.113; or
- ☐ A notice of allowance under § 1.311,
- whichever comes first, but before payment of the issue fee, and is accompanied by
- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;
- b. The attached petition requesting consideration of this Information Disclosure Statement; and
- c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.
7. **Certification Pursuant to 37 CFR 1.97(e).**
- ☐ The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

RECEIVED


AUG 27 2001

TECH CENTER 1600/2900

8. Fee Payment Being Made.

- ☐ Enclosed
- ☐ \$180.00 fee for submission under 37 CFR § 1.97(c).
- ☐ \$180.00 fee for submission under 37 CFR § 1.97(d).
- ☐ A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- ☐ Charge the fee to Deposit Account No. 18-0582. A duplicate copy of this communication is attached.
- ☒ The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 18-0582. A duplicate copy of this communication is enclosed.

Respectfully submitted,




Frederick H. Colen, Esq.  
Reg. No. 28,061

Dated: August 22, 2001

REED SMITH LLP  
P.O. Box 488  
Pittsburgh, PA 15230  
(412) 288-4164

Attorney for Applicants

RECEIVED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE    INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))	ATTY. DOCKET NO.  00-149	SER. NO.  09/810,700	AUG 27 2001 TECH CENTER 1600/2900
	APPLICANT  Wong et al.		
	FILING DATE  March 16, 2001	GROUP  unknown	

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. <sup>1</sup>	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
		6, 051, 230	Apr. 18, 2000	Thorpe et al.		Jun. 1, 1995
		5, 965, 132	Oct. 12, 1999	Thorpe et al.	424/149	Dec. 5, 1994
		5, 855, 866	Jan. 5, 1999	Thorpe et al.	424/1.49	Mar. 2, 1994
		6, 261, 535	Jul. 17, 2001	Thorpe et al.	424/1.49	Dec. 8, 1998


## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No. <sup>1</sup>	
		Ghose et al., Preparation of antibody-linked cytotoxic agents. Methods Enzymol. 93: 280-333, 1983.
		Ghose et al., The design of cytotoxic-agent-antibody conjugates. Crit. Rev. Ther. Drug. Carrier Syst. 3(4):263-359. 1987.
		Pierschbacher M.D. and Ruoslahti E. The cell attachment activity of fibronectin can be duplicated by small fragments of the molecule. Nature 1984; 309:30.
		Koivunen E, Gay D, Ruoslahti E. Selection of peptides binding to the $\alpha_5\beta_1$ integrin from phage display library. J Biol Chem 1993; 268: 20205.
		Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the $\alpha_5\beta_1$ integrin from a phage display library. J Cell Biol 1994; 124:373.
		Healy JM, Murayama O, Maeda T, et al. Peptide ligands for integrin $\alpha_5\beta_3$ selected from random phage display libraries. Biochemistry 1995; 34:3948.
		Pasqualini R, Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380:364.
		Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102:430.
		Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Ca Res 2000; 60:722.
		Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315.
		Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249:386.
		Clackson T, Wells JA. In vitro selection from protein and peptide libraries. Trends Biothechnol 1994; 12:173.

AUG 27 2001


TECH CENTER 1600/2900

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>		<b>ATTY. DOCKET NO.</b>  00-149	<b>SER. NO.</b>  09/810,700
 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>APPLICANT</b>  Wong et al.	
		<b>FILING DATE</b>  March 16, 2001	<b>GROUP</b>  unknown

(37 CFR 1.98(b))

Examiner Initial	Cite No. <sup>1</sup>	
		Colas P, Cohen B, Jessen T, et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. <i>Nature</i> 1996; 380:548.
		Lu Z, Murray KS, van Cleave V, et al. Expression of thioredoxin random peptide libraries on <i>Escherichia coli</i> ( <i>E. coli</i> ) cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. <i>Bio/Technology</i> (NU) 1995; 13:366.
		Baatout S. Endothelial differentiation using Matrigel ( <i>Review</i> ). <i>Anticancer Res</i> 1997; 17:451.
		Zhu D, Pauli BU. Generation of monoclonal antibodies directed against organ-specific endothelial cell surface determinants. <i>J Histochem Cytochem</i> 1991; 39:1137.
		Pierschbacher MD, Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. <i>Proc Natl Acad Sci USA</i> 1984; 81:5985.
		Yamada KM, Kennedy DW. Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. <i>J Cell Biol</i> 1984; 99:29.
		Gartner TK, Bennett JS. The tetrapeptide analog of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. <i>J Biol Chem</i> 1985; 260:11891.
		Plow EF, Pierschbacher MD, Ruoslahti E, et al. The effect of Arg-Gly-Asp containing peptides on fibrinogen and von Willebrand factor binding to platelets. <i>Proc Natl Acad Sci USA</i> 1985; 82:8057.
		Brown CK, Modzelewski RA, Johnson CS, and Wong MKK. A novel approach for the identification of unique tumor vasculature binding peptides using an <i>E. coli</i> peptide display library. <i>Ann. Of Surg. Onc.</i> 2000; 7(10): 743-749.
		Suzuki S, Oldberg A, Hayman EG, et al. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. <i>EMBO J</i> 1985; 4:2519.
		Gardner JM, Hynes RO. Interaction of fibronectin with its receptor on platelets. <i>Cell</i> 1985; 42:439.
		Ito Y, Iwamoto Y, Tanaka K, et al. A quantitative assay using basement membrane extracts to study tumor angiogenesis <i>in vivo</i> . <i>Int J Cancer</i> 1996; 67:148.

RECEIVED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE   INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 00-149	SER. NO. 09/810,700
	APPLICANT Wong et al.	
	FILING DATE March 16, 2001	GROUP unknown

Examiner Initial	Cite No. <sup>1</sup>	
_____		Modzelewski RA, Davies P, Watkins SC, Auerback R, Chang M-J, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Ca Res 1994, 54:336-339.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.